Company Information
CIN
Status
Date of Incorporation
29 March 2007
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2022
Paid Up Capital
10,625,000
Authorised Capital
11,000,000
Directors
Manikreddy Pullagurla
Director/Designated Partner
over 2 years ago
over 2 years ago
Madhusudana Rao Kothapalli
Director/Designated Partner
about 7 years ago
about 7 years ago
Harcharan Singh
Director/Designated Partner
about 10 years ago
about 10 years ago
Jagadeesh Babu Rangisetty
Director/Designated Partner
over 18 years ago
over 18 years ago
Past Directors
Ravibabu Kothapalli
Director
over 18 years ago
over 18 years ago
Patents
The present invention describes an improved method for the synthesis of substantially pure Permethrin (1) having purity greater than 99.5% by Gas Chromatography (GC). The invention also relates to a purification process of Permethrin by recrystallization from methanol-water mixture.
The present invention relates to an improved process for the preparation of (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone (Tolcapone).
The invention relates to an improved process for the preparation N-[4-[[4-(diethyl amino) phenyl] (2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium inner salt sodium salt (Isosulfan blue) of formula I. The invention also relates to highly pure novel crystalline form of Isosulfan blue (I)...
The invention provides a novel polymorph of Regadenoson. More particularly, the invention provides propylene glycol solvate of Regadenoson. The invention also provides a process for the preparation of propylene glycol solvate of Regadenoson.
The present invention relates to a process for the preparation of 4-{5-[ Bis -(2- hydroxyl-ethyl)-amino]-1-methyl-1H-Benzoimidazol-2yl}-butyric acid ethyl ester of formula IV, a key intermediate in the process for the preparation of Bendamustine HCI (I).
The present invention describes an improved process for the preparation of Dabigatran Etexilate (Formula-I), a pharmaceutically acceptable salt for the treatment of thromboses, cardiovascular diseases etc. and intermediates involved in the synthesis.
The present invention relates to an improved process for the purification of polyaminocarboxylates such as DOTA, DTPA, D03A-butrol, BOPTA.
The present invention relates to a novel crystalline polymorphic form D of Eletriptan Hydrobromide characterized by an XRD pattern with two theta values at 18.8., 20.5, 23.7,24.2. The present invention also relates to a process for making Form D comprising treating Eletriptan in water or in a suitable organic solven...
FIELD OF INVENTION:
The invention relates to a novel process for the preparation of 5-substituted insole derivative, Eleptriptan and its intermediates thereof, also preventing the formation of dimmer as an impurity.
The present invention relates to a novel process for the preparation of sodium 7-((3-Chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoate and intermediates. The invention also encompasses isolation of an essentially non-hygroscopic compound which is substantially pure.
...
The present invention relates to a process for the preparation of substantially pure Taurolidine.
The present invention describes an improved process for the preparation of substantially pure 1-(1-(benzo[b]thiophen-2-yl) ethyl)-1-hydroxyurea, also known as Zileuton (I).
The present invention relates to a novel method of resolving 2-amino-3-(4-methoxyphenyl)-2-methylpropanenitrile (IV) and preparation of substantially pure (S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid (I) thereof.
(I)
The present invention relates to an improved method for the synthesis of sulfobutylether beta cyclodextrin sodium and to provide an amorphous form of sulfobutylether beta cyclodextrin sodium having a 1,4-butane sultone content less than 0.5 ppm. The present invention further provides sulfobutylether beta cyclodextri...
ABSTRACT
The present invention relates to an improved process for the preparation of Valbenazine tosylate (1) with purity greater than 99.0% and process for the preparation of novel solid forms of Valbenazine tosylate (1).
The present invention relates to an improved process for the preparation of Naphazoline hydrochloride (1). It further relates to the purification process to yield Naphazoline hydrochloride (1) with purity more than 99.0 %.
ABSTRACT
The present invention relates to a novel crystalline forms of Crisaborole (1). More particularly, the present invention relates to the process for the preparation of solvated crystalline forms of Crisaborole (1) which may include ethanol and n-butanol hemi-solvates with purity greater than 99.0%.
...
The present invention relates to the process for the preparation of solid forms of Betrixaban maleate (1). The present invention further relates to the process for the preparation of amorphous forms, crystalline forms and solid dispersions of Betrixaban maleate (1) with suitable pharmaceutical acceptable excipients....
The present invention relates to an improved process for the preparation of pharmaceutical grade of Sucroferric oxyhydroxide (1). More particularly, the present invention relates to a process for the preparation of Sucroferric oxyhydroxide (1) specific surface area of more than 16 m2/gm.
The present invention relates to an improved process for the preparation of Chlorpromazine hydrochloride (1) with purity more than 99.0% (w/w). It further relates to the process for the purification of Chlorpromazine hydrochloride (1).
ABSTRACT
The present invention relates to an improved process for the preparation of Ribociclib succinate (1) and the novel crystalline forms thereof. More particularly the invention relates to the process for the preparation of novel crystalline forms of Ribociclib succinate (1).
ABSTRACT
The present invention relates to an improved process for the preparation of 4-amino-5-hexenoic acid (1) with purity greater than 99.0% by HPLC.
The present invention relates to solid forms of 4-{8-amino-3-[(2S)-l-(but-2-ynoyl) pyrrolidin-2-yl] imidazo [1,5-a] pyrazin-l-yl)}-N-(pyridine-2-yl) benzamide (Acalabrutinib)
The present invention relates to an improved process for the preparation of Tiopronin (1) with greater than 99.0% purity. It further relates to the crystalline forms of Tiopronin (1).
The present invention relates to an improved process for the preparation of Nitazoxanide (I) with more than 99.0% purity by HPLC.
The present invention relates to an improved process for the preparation of
macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-l,4,7,10-
tetraazacyclododecane-l,4,7-triyl) triacetic acid of formula (1). The present
invention further relates to the process for the preparation of metal complexes of
macrocyclic che...
ABSTRACT
The present invention relates to an improved process for the preparation of Cariprazine hydrochloride (1) with purity greater than 99.0%. It further provides a process for the control of dimer impurity 4-(2,3-dichlorophenyl)-N-((trans)-4-(2-(4-(2,3-dichloro phenyl) piperazin-1-yl) ethyl) cyclohexyl) pipera...
The present invention relates to an improved process for the synthesis of pure D-Penicillamine (I). It further relates to a novel process for the separation of isomers using D-tartaric acid having purity greater than 99.0% by HPLC
The present invention relates to the process for preparing solid forms of 4-(4-{[2-(4-chlorophenyl)-4,4dimethylcyclohex-1 -en-1 -yl] methyl} piperazin-1 -yl)-N-( { 3 -nitro-4-[(tetrahydro-2H-pyran-4ylmethyl) amino] phenyl} sulfonyl)-2-(lH-pyrrolo[2,3-B] pyridin-5-yloxy) benzamide) (Venetoclax)
ABSTRACT
The present invention relates to the crystalline forms of (3a,5p\6a,7a)-6-ethyl-3,7-dihydroxycholan-24-oic acid, commonly known as Obeticholic acid (1) and process for the preparation of the same.
The present invention describes an improved process for the preparation of substantially pure 7-chloro-l,2,3,4-tetrahydro-2-methyl-3-(2-melhylphenyl)-4-oxo-6-quinazolinesulfonamide (Metolazone) (1).
The present invention relates to an improved process for the preparation of 4-amino-N-[2-(diethylamino) ethyl] benzamide; hydrochloride (I) with purity more than 99.0 % by HPLC.
The present invention relates to a process for the preparation of Vasopressin of formula (20) Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (S-S bridge between Cysteines). The present invention further relates to a process for the purification of Vasopressin intermediate of formula (20).
The present invention relates to an improved process for the preparation of 2,2",2"-(10-((2R,3S)-l,3,4-trihydroxy butan-2-yl)-l,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid, gadolinium (III) with iron metal content less than 5ppm and free gadolinium content less than lOppm , which is represented by the f...
The present invention relates to an improved process for the preparation of N-[(4-fiuorophenyl) methyl]-N-(l-methyl-4-piperidinyl)-N"-[[4-(2-methylpropoxy) phenyl] methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) of formula (1).
The present invention relates to the process for preparing crystalline forms of Ribociclib succinate (1).
The present invention relates to an improved process for the preparation of substantially pure Mexiletine hydrochloride (1) with purity greater than 99.0 %.
ABSTRACT
The present invention relates to a novel process for the preparation of Acalabrutinib (1) with purity greater than 99% and its intermediate compounds thereof.
ABSTRACT
The present invention relates to the process for the preparation of (1:1) mixture of Crisaborole (1) with propylene glycol solution.
ABSTRACT
The present invention relates to an improved process for the preparation of substantially pure Cannabidiol (1) having greater than 99% purity.
Cx OH
Cannabidiol (1)
The present invention relates to an improved process for the preparation of 1,4,7,10-tetrazacyclododecane (1) and its salts. More particularly, the present invention provides process for the preparation of 1,4,7,10-tetrazacyclododecane (1) with more than 99.0% purity.
The present invention relates to an improved process for the preparation of substantially pure propane-1,2,3 -triyl tris(4-phenylbutanoate) (Glycerol phenylbutyrate) (1) with purity greater than 99%.
The present invention relates to an improved process for the preparation of Fenoprofen calcium (1). Further, the present invention provides Fenoprofen calcium (1) having purity greater than 99.0 %.
The present invention provides an improved process for the preparation of Valsartan (1). It further relates to a process for the purification of Valsartan having purity greater than 99.0% by HPLC.
The present invention relates to an improved process for the preparation of Nimodipine (1). It further relates to the process for the purification of Nimodipine (1) with greater than 99.0% purity.
The present invention relates to an improved process for the preparation of Erythromycin Lactobionate (1) having purity more than 98.0%. It further relates to the preparation of crystalline hydrated forms of Erythromycin Lactobionate (1).
ABSTRACT
The present invention relates to solid forms of Apalutamide (1). More particularly the invention relates to solid forms comprising of crystalline forms Al, and A2 of Apalutamide (1), amorphous form of Apalutamide (1) and the process thereof.
ABSTRACT
The present invention relates to an improved process for the preparation of
Primidone (1) with purity greater than 99.0% by HPLC.
The present invention relates to an improved process for the preparation of Fluphenazine dihydrochloride (1) with purity greater than 99.0%. More particularly, the present invention provides process for the purification of Fluphenazine dihydrochloride (1).
ABSTRACT
The present invention relates to a novel process for the preparation of 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-l-oxopropyl] [(lS)-l-(4-phenyl-lH-imidazol-2-yl) ethyl] amino] methyl]-2-methoxybenzoic acid (Eluxadoline (1) and its intermediates thereof.
The present invention relates to the process for the preparation of novel solid forms of Abemaciclib (1). More particularly, it relates to the process for the preparation of crystalline form 1, form 2, form 3, form 4, form 5 and form 6, form 7, form 8, form 9, form 10, form 11, form 12 and amorphous form of Abemacic...
The present invention relates to a novel process for the preparation of amorphous form of Elagolix sodium (1) with purity more than 99.0% (w/w) by HPLC. It further provides an improved process for the preparation of Elagolix sodium (1) used herein.
The present invention relates to a novel process for the preparation of substantially pure Crisaborole (I).
This invention relates to an improved method for the preparation of highly or substantially pure Indigotindisulfonate sodium (1). It further relates to the novel crystalline form I of Indigotindisulfonate sodium (1) and the process for its preparation.
The present invention relates to an improved method for the synthesis of substantially pure 1,2-ethanediamine, N, N'-bis(2-aminoethyl)-dihydrochloride (I).
(Trientine dihydrochloride)
(I)
The present invention relates to an improved method of preparation of substantially pure Methazolamide (I) with more than 99.5 % purity.
The present invention relates to an improved method for the preparation of substantially pure crystalline Dantrolene sodium (I), having purity of greater than 99.5% as determined by HPLC.
The present invention describes an improved process for the synthesis of substantially pure Acrivastine (I), which is having purity greater than 99.5% by HPLC.
The present invention describes an improved method for the synthesis of substantially pure 6-aminohexanoic acid (6-aminocaproic acid) (I) having purity greater than 99.5% as determined by HPLC.
The present invention relates to an improved process for the preparation of Nitisinone of formula (1) having purity greater than 99.0% by HPLC. It further relates to crystalline forms of Nitisinone of formula (1) and the process for the preparation of thereof.
ABSTRACT
The present invention relates to an improved process for the preparation of 3,4-dihydroxy-a-[(isopropylamino) methyl] benzyl alcohol hydrochloride (I), having purity greater than 99.0% as determined by HPLC.
ABSTRACT
The present invention relates to novel process for the preparation of 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-l-oxopropyl] [(lS)-l-(4-
phenyl-lH-imidazol-2-yl) ethyl] amino] methyl] -2-methoxybenzoic acid commonly known as Eluxadoline (1) and its intermediates thereof.
...
The present invention relates to an improved process for the preparation of Chlorambucil of formula (1), having purity greater than 99.0% as determined by HPI
ABSTRACT
The present invention relates to an improved process for the preparation of Nisoldipine (1) with purity greater than 99.0 % by HPLC. The process also relates to a crystalline form of Nisoldipine (1) and a process for the preparation thereof.
The present invention relates to the solid forms of Brexpiprazole and the process for the preparation thereof, specifically the present invention relates to a process for the preparation of solid dispersion forms of Brexpiprazole. Further, the present invention also provides process for the preparation of Brexpipraz...
ABSTRACT
The present invention relates to an improved process for the preparation of substantially pure Indocyanine green of formula (1) with purity greater than 99.0%. More particularly, the present invention relates to the process for the preparation of Indocyanine green of formula (1) and its intermediates there...
The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to the process for the preparation of metal complexes of macrocyclic chelant ...
The present invention relates to an improved process for the preparation of Clofarabine
The present invention relates to an improved process for the preparation of Sugammadex sodium (1). It further relates to a novel process for the purification of Sugammadex sodium (1) having impurity A less than 2%(w/w) and impurity E less than0.1%(w/w)
The present invention relates to an improved process for the preparation of Sodium nitroprusside (1) More particularly the present invention relates to a process for the purification of Sodium nitroprusside (1) with greater than 99.0% purity.
The present invention relates to an improved process for the preparation of 5-chlorobenzo[d]oxazol-2(3H)-one (1) with purity greater than 99.0 %. More particularly, the present invention provides process for the purification of -chlorobenzo[d]oxazol-2(3H)-one (1), which is also known as Chlorzoxazone.
...
The present invention relates to an improved process for the preparation of Diazoxide (I) with more than 99.0% purity. It further relates to the process for purification of Diazoxide (I) intermediates of formula (V), (III) and (II).
The present invention relates to a method for preparing a peptide Angiotensin-II acetate of formula (1) using solid phase synthesis. It further relates to the solid phase synthesis of Angiotensin-II acetate of formula (1) containing Fmoc and Boc protected amino acids residues.
ABSTRACT "NOVEL PROCESS FOR THE PREPARATION OF BILASTINE AND
INTERMEDIATES THEREOF"
The present invention relates to a novel process for the preparation of 2-[4-[2-[4-
[1-(2-ethoxyethyl) benzimidazol-2-yl] piperidin-1-yl] ethyl] phenyl]-2-methyl propionic acid (I). It further relates to a process for the purifi...
ABSTRACT
“AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- α
-METHYL-3-(TRIFLUOROMETHYL)PHENETHYLAMINE
HYDROCHLORIDE”.
The present invention relates to an improved process for the preparation of N-ethyl-
α-methyl-3-(trifluoromethyl) phenethylamine hydrochloride (1), having purity
greater than 99.5% by ...
The present invention relates to a pure amorphous form of 2-chloro-2'-deoxy-adenosine (Cladribine (1)) complex with HPßCD, wherein the percentage of crystallinity is less than 0.5% (w/w), more preferably less than 0.2% (w/w). The present invention further relates to a process for the preparation of amorphous form of...
The present invention relates to an improved process for the preparation of Prucalopride succinate (1) having purity greater than 99.0%.
The present invention relates to process for the preparation Tafamidis meglumine (1). It also relates to the process for the preparation of Tafamidis solid dispersion forms with pharmaceutically acceptable excipients. Further, the present invention discloses preparation of amorphous Tafamidis (2).
...
The present invention relates to an improved process for the preparation of Rupatadine fumarate (1). It further relates to the process for the purification of Rupatadine fumarate (1) with purity greater than 99.0% (w/w) and preferably greater than 99.5% (w/w) by High-performance liquid chromatography (HPLC).
...
The present invention relates to solid forms of Ertugliflozin L-pyroglutamic acid (1). It further discloses the solid dispersions of Ertugliflozin L-pyroglutamic acid (1) with a suitable pharmaceutically acceptable excipient, physical mixtures of Ertugliflozin free base, L-pyroglutamic acid and a suitable pharmaceut...
The present invention relates to an improved process for the preparation of L-glutamine (1). It further relates to process for the purification of L-glutamine (1) with purity greater than 99.0% (w/w), preferably greater than 99.5% (w/w) by High-performance liquid chromatography (HPLC).
L-glutamine (1)
...
The present invention relates to a process for the preparation of 7-(4,7-diazaspiro [2.5] octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b] pyridazin-6-yl) pyrido-4H-[1,2-a] pyrimidin-4-one represented by the following structural formula (1) by employing novel intermediates of formulae (5), (6), (7), (9) and (13).
The p...
"SOLID DISPERSIONS OF 7-(4,7-DIAZASPIRO [2.5] OCTAN-7-YL)-2-
(2,8-DIMETHYLIMIDAZO[1,2-B] PYRIDAZIN-6-YL) PYRIDO-4H-[1,2-A]
PYRIMIDIN-4-ONE"
The present invention relates to solid dispersions of 7-(4,7-diazaspiro [2.5] octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b] pyridazin-6-yl) pyrido-4H-[1,2-a] pyrimidin-4-one (1) ...
Enclosed
"SOLID FORMS OF DISODIUM 3,3’-DIOXO-[?2,2’-BIINDOLINE]-5,5’-
DISULFONATE AND PROCESS FOR ITS PREPARATION THEREOF"
The present invention relates to solid forms of Disodium 3,3’-dioxo-[?2,2’-biindoline]-5,5’-disulfonate and process for its preparation thereof. The present invention also relates to amorphous form and...
ABSTRACT
"AN IMPROVED PROCESS FOR THE PREPARATION OF ZINC SULFATE HEPTAHYDRATE"
The present invention relates to an improved process for the preparation of zinc sulfate heptahydrate (I), having quality specifications as per new FDA-imposed quality standards and the ICH Q3D guidelines.
(I)
...
ABSTRACT
"AN IMPROVED PROCESS FOR THE PREPARATION OF 1-[[N-METHYL-N-3-[(METHYLAMINO)ACETOXYMETHYL] PYRIDIN-2-YL] CARBAMOYLOXY] ETHYL- 1-[(2R,3R)-2-(2,5-DIFLUOROPHENYL)-2-HYDROXY-3-[4-(4-CYANOPHENYL) THIAZOL-2-YL] BUTYL]-1H- [1,2,4]-TRIAZO-4-IUMSULFATE"
The present invention relates to an improved process for the p...
ABSTRACT
“A PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM OF
TAFAMIDIS”
The present invention relates to a stable crystalline form of Tafamidis having characteristic 2-theta peaks at 13.6±0.2, 20.4±0.2 and 27.5±0.2. The present invention
provides Tafamidis having particle size (d90) less than 100microns. Furth...
ABSTRACT
"A NOVEL PROCESS FOR THE PREPARATION OF AMORPHOUS
SOLID DISPERSION OF 1-{3-[3-(4-CHLOROPHENYL) PROPOXY]
PROPYL} PIPERIDINE, HYDROCHLORIDE WITH HYDROXYPROPYL
BETA-CYCLODEXTRIN (HPßCD)"
The present invention relates to a novel process for the preparation of amorphous solid dispersion of 1-{3-[3-(4-chloro...
ABSTRACT
"PURIFICATION METHOD FOR 1-[[N-METHYL-N-3-
[(METHYLAMINO)ACETOXYMETHYL] PYRIDIN-2-YL]
CARBAMOYLOXY] ETHYL- 1-[(2R,3R)-2-(2,5-DIFLUOROPHENYL)-2-
HYDROXY-3-[4-(4-CYANOPHENYL) THIAZOL-2-YL] BUTYL]-1H-
[1,2,4]-TRIAZO-4-IUMSULFATE"
The present invention relates to a method for the purification of 1-[[N-met...
ABSTRACT
"NOVEL PROCESS FOR THE PREPARATION OF 2-HYDROXY-6-((2-(1-
ISOPROPYL-1H-PYRAZOL-5-YL) PYRIDINE-3-YL) METHOXY)
BENZALDEHYDE"
The present invention relates to a cost-effective, commercially viable and
industrially advantageous process for the preparation of 2-hydroxy-6-((2-(1-
isopropyl-1H-pyrazol-5-yl) ...
ABSTRACT
"NOVEL SOLID FORMS OF 8-QUINOLINESULFONAMIDE, N-[4-
[[4(CYCLOPROPYLMETHYL)-1-PIPERAZINYL] CARBONYL]
PHENYL]-SULFATE AND ITS PROCESS FOR PREPARATION
5 THEREOF"
The present invention relates to solid forms of 8-quinolinesulfonamide, N- [4-
[4(cyclopropyl methyl)-1-piperazinyl] carbonyl] phenyl]-sulfate ...
ABSTRACT
"IMPROVED PROCESS FOR THE PREPARATION OF SODIUM 8-[(2-
HYDROXYBENZOYL) AMINO] OCTANOATE”
The present invention relates to an improved process for the preparation of Sodium
5 8-[(2-hydroxybenzoyl) amino] octanoate is having purity greater than 99.5% by
High performance liquid chromatography (HPLC).
...
ABSTRACT
"PROCESS FOR THE PREPARATION OF (R)-3-(4-(7H-PYRROLO[2,3D]
PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-
CYCLOPENTYLPROPANENITRILE PHOSPHATE"
The present invention relates to a process for the preparation of (R)-3-(4-(7Hpyrrolo[2,3d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
phosphate (1) havi...
ABSTRACT
“PROCESS FOR THE PREPARATION OF SUVOREXANT”
The present invention relates to a process for the preparation of Suvorexant having a purity greater than 99.5% by High-performance liquid chromatography (HPLC). The present invention relates to pure solid forms of Suvorexant.
ABSTRACT
"SOLID FORMS OF 1-[3-(AMINOMETHYL) PHENYL]-N-(5-{(R)-(3-
CYANOPHENYL) [(CYCLOPROPYLMETHYL)AMINO] METHYL}-2-
FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-
CARBOXAMIDE BISHYDROCHLORIDE"
The present invention provides solid forms comprising amorphous solid dispersion
of 1-[3-(aminomethyl) phenyl]-N-(5...
ABSTRACT
“A PROCESS FOR THE PREPARATION OF SOLID FORMS OF
SUVOREXANT”
The present invention relates to a process for the preparation of solid forms of
5 Suvorexant (1) with at least one pharmaceutically acceptable excipient. It further
relates to a process for the preparation of amorphous form of Suvorexant (1)...
ABSTRACT
“A PROCESS FOR THE PREPARATION OF SOLID FORMS OF 7-(4,7-
DIAZASPIRO [2.5] OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]
PYRIDAZIN-6-YL) PYRIDO-4H-[1,2-A] PYRIMIDIN-4-ONE”
5 The present invention relates to a process for the preparation of solid forms of 7-
(4,7-diazaspiro [2.5] octan-7-yl)-2-(2,8-dimethyli...
"IMPROVED PROCESS FOR THE PREPARATION OF 1, 5-DIHYDRO-4
H-PYRAZOLO [3, 4- D] PYRIMIDIN-4-ONE"
The present invention relates to an improved process for the preparation of 1, 5-
dihydro-4 H-pyrazolo [3, 4- d] pyrimidin-4-one (1), having purity greater than
99.5% by High performance liquid chromatography (HPLC).
A...
"IMPROVED PROCESS FOR THE PREPARATION OF FLUORESCEIN
SODIUM"
The present invention relates to a process for the preparation of Fluorescein sodium
(1) having a purity greater than 99.5% by HPLC. It further relates to crystalline
form of Fluorescein free base (2) and Fluorescein sodium (1).
...
"IMPROVED PROCESS FOR THE PREPARATION OF [1R- [1α,2
α(1'R*,2'R*)]]-2,2'- [1,5-PENTANEDIYLBIS [OXY (3-OXO-3,1
PROPANEDIYL)]] BIS [1-[(3,4-DIMETHOXYPHENYL) METHYL]-1,2,3,4-
TETRAHYDRO-6,7-DIMETHOXY-2-METHYLISOQUINOLINIUM]
DIBENZENESULFONATE"
The present invention relates to an improved process for the preparation...
"IMPROVED PROCESS FOR THE PREPARATION OF CALCIUM
GLUCONATE"
The present invention relates to an improved process for the preparation of Calcium
gluconate (1), having purity greater than 99.5% by High performance liquid
chromatography (HPLC).
The present invention relates to an oral pharmaceutical composition of
isavuconazonium or its pharmaceutically acceptable salts thereof. The present
invention also relates to a process for preparing an oral pharmaceutical
composition of isavuconazonium or its pharmaceutically acceptable salts thereof.
10 It furt...
ABSTRACT
“PROCESS FOR THE PREPARATION OF VILOXAZINE
HYDROCHLORIDE”
The present invention relates to a process for the preparation of Viloxazine
5 Hydrochloride having a purity greater than 99.5% by High-performance liquid
chromatography (HPLC). It further relates to crystalline form of Viloxazine
Hydrochloride...
ABSTRACT
"NOVEL CRYSTALLINE FORM OF 2-HYDROXY-6-((2-(1-ISOPROPYL1H-PYRAZOL-5-YL) PYRIDINE-3-YL) METHOXY) BENZALDEHYDE"
The present invention relates novel crystalline form of 2-hydroxy-6-((2-(1-
5 isopropyl-1H-pyrazol-5-yl) pyridine-3-yl) methoxy) benzaldehyde (1) and process
for its preparation thereof. The com...
The present invention relates to crystalline form of Mitapivat hemisulfate (1). The
present invention further relates to a process for preparing crystalline form of
5 Mitapivat hemisulfate (1) and pharmaceutical compositions thereof. The crystalline
form of Mitapivat hemisulfate (1) has been characterized by X-Ra...
ABSTRACT
"A PROCESS FOR THE PREPARATION OF SOLID FORMS N-(4-{1[(2,6-
DIFLUOROPHENYL) METHYL]-5-[(DIMETHYLAMINO)METHYL]-3-
(6-METHOXYPYRIDAZIN-3-YL)-2,4-DIOXO-1,2,3,4
5 TETRAHYDROTHIENO[2,3-D] PYRIMIDIN-6-YL} PHENYL)-N’-
METHOXYUREA"
The present invention relates to a process for the preparation of solid forms ...
The present invention relates to a process for the preparation of solid-state forms of
N-[4(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1Hpyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride. More specifically, the present invention relates to a process for the preparation of solid dispersi...
Solid Forms Of N (8 [2 Hydroxybenzoyl] Amino) Caprylic Acid Sodium And Method Of Preparation Thereof
ABSTRACT
“STABLE SOLID DISPERSIONS OF SALCAPROZATE WITH VARIOUS ACTIVE
PHARMACEUTICAL INGREDIENTS”
The present invention relates to solid forms of N-(8-[2-Hydroxybenzoyl]-Amino) caprylic acid
5 sodium, specifically solid dispersion of N-(8-[2-Hydroxybenzoyl]-Amino) caprylic acid
sodium with one or more active p...
ABSTRACT
"PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM OF N, N'-
BIS(2-AMINOETHYL)-1,2-ETHANEDIAMINE DIHYDRATE"
The present invention relates to process for the preparation of crystalline form of N,
N'-bis(2-aminoethyl)-1,2-ethanediamine dihydrate (I). It further relates to crystalline
form of N, N'-bis(2-am...
“Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof”
The disclosure relates to a novel liquid dosage form comprising composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and process of preparation thereof. The disclosure also relates to...
"SOLID DISPERSIONS OF 5-AMINO-3-{4-[(5-FLUORO-2-METHOXYBENZAMIDO) METHYL]PHENYL}-1-[(2S)-1,1,1-
TRIFLUOROPROPAN-2-YL]-1H-PYRAZOLE-4-CARBOXAMIDE"
The present invention relates to a solid dispersion of 5-amino-3-{4-[(5-fluoro-2- methoxybenzamido)methyl]phenyl}-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-pyrazole-4-carbox...
"AMORPHOUS FORM OF FLUORESCEIN SODIUM AND PROCESS
FOR ITS PREPARATION THEREOF"
The present invention relates to amorphous form of Fluorescein sodium (1) and
process for its preparation thereof. It further relates to amorphous form of
Fluorescein sodium (1) prepared in the present invention is having purity great...
"A PROCESS FOR THE PREPARATION OF 8-
QUINOLINESULFONAMIDE, N- [4-[4(CYCLOPROPYL METHYL)-1-
PIPERAZINYL] CARBONYL] PHENYL]-SULFATE"
The present invention relates to a process for the preparation of 8-
quinolinesulfonamide, N- [4-[4(cyclopropyl methyl)-1-piperazinyl] carbonyl]
phenyl]-sulfate represented by the f...
" PROCESS FOR THE PREPARATION OF SODIUM ACETATE"
The present invention relates to an improved process for the preparation of
anhydrous sodium acetate (1), having quality specifications as per new FDA
imposed quality standards and the ICH Q3D guidelines.
“IMPROVED PROCESS FOR THE PREPARATION OF
LANREOTIDE ACETATE”
The present invention relates to an improved process for the preparation of Lanreotide Acetate (1) with purity greater than 99.0% (w/w) by flash chromatography or preparative HPLC.
"A PROCESS FOR THE PREPARATION OF N-(4-{1[(2,6-
DIFLUOROPHENYL) METHYL]-5-[(DIMETHYLAMINO)METHYL]-3-
(6-METHOXYPYRIDAZIN-3-YL)-2,4-DIOXO-1,2,3,4
TETRAHYDROTHIENO[2,3-D] PYRIMIDIN-6-YL} PHENYL)-N’-
METHOXYUREA"
The present invention relates to a process for the preparation of N-(4-{1[(2,6-
difluorophenyl) methy...
“A PROCESS FOR THE PREPARATION OF 4-[(3-{[4-(CYCLOPROPYL
CARBONYL) PIPERAZIN-1-YL] CARBONYL}-4-FLUOROPHENYL)
METHYL] PHTHALAZIN -1(2H)-ONE”
The present invention relates to a process for the preparation of 4-[(3-{[4-(cyclopropyl
carbonyl) piperazin-1-yl] carbonyl}-4-fluorophenyl) methyl] phthalazin -1(2H)-one
r...
?A PROCESS FOR THE PREPARATION OF (±)-4’-[(7-CHLORO-2,3,4,5-
TETRAHYDRO-5-HYDROXY-1H-1-BENZAZEPIN-1-YL) CARBONYL]-OTOLU-
M-TOLUIDIDE ?
The present invention relates to a process for the preparation of (±)-4’-[(7-chloro-
2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl) carbonyl]-o-tolu-m-toluidide,
represented...
?A NOVEL PROCESS FOR THE PREPARATION OF (6R)-6-(2-(N-(4-(2-(ETHYLAMINO) ETHYL) BENZYL)-N-ETHYLAMINO)-4-METHOXYPHENYL)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL DIHYDROCHLORIDE AND IT’S INTEMEDIATES ?
The present invention relates to a process for the preparation of (6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylam...
“Modified release formulations of viloxazine”
Modified release formulations of viloxazine and methods of administering the same are disclosed.
Registered Trademarks
[Class : 42] Scientific And Technological Services, Research And Development Services.
[Class : 35] Advertising, Business Management, Business Administration, Office Functions.
[Class : 42] Scientific And Technological Services, Research And Development Services.
View +1 more Brands for Biophore India Pharmaceuticals Private Limited.
Charges
25 March 2015
Kotak Mahindra Bank Limited
91 Crore
14 November 2009
Andhra Bank
21 Crore
27 October 2012
Reliance Capital Ltd
50 Lak
31 March 2021
Hdfc Bank Limited
1 Crore
15 February 2021
Hdfc Bank Limited
1 Crore
23 September 2020
Kotak Mahindra Bank Limited
5 Crore
07 January 2020
Axis Bank Limited
4 Crore
26 September 2019
Axis Bank Limited
22 Lak
26 September 2019
Axis Bank Limited
20 Lak
26 September 2019
Axis Bank Limited
24 Lak
12 July 2022
Others
0
25 March 2015
Others
0
07 January 2020
Axis Bank Limited
0
23 September 2020
Others
0
31 March 2021
Hdfc Bank Limited
0
26 September 2019
Axis Bank Limited
0
26 September 2019
Axis Bank Limited
0
26 September 2019
Axis Bank Limited
0
15 February 2021
Hdfc Bank Limited
0
27 October 2012
Reliance Capital Ltd
0
14 November 2009
Andhra Bank
0
12 July 2022
Others
0
25 March 2015
Others
0
07 January 2020
Axis Bank Limited
0
23 September 2020
Others
0
31 March 2021
Hdfc Bank Limited
0
26 September 2019
Axis Bank Limited
0
26 September 2019
Axis Bank Limited
0
26 September 2019
Axis Bank Limited
0
15 February 2021
Hdfc Bank Limited
0
27 October 2012
Reliance Capital Ltd
0
14 November 2009
Andhra Bank
0
12 July 2022
Others
0
25 March 2015
Others
0
07 January 2020
Axis Bank Limited
0
23 September 2020
Others
0
31 March 2021
Hdfc Bank Limited
0
26 September 2019
Axis Bank Limited
0
26 September 2019
Axis Bank Limited
0
26 September 2019
Axis Bank Limited
0
15 February 2021
Hdfc Bank Limited
0
27 October 2012
Reliance Capital Ltd
0
14 November 2009
Andhra Bank
0
Documents
Form CHG-1-02122020-signed
CERTIFICATE OF REGISTRATION OF CHARGE-20201202
Form CHG-1-30102020-signed
CERTIFICATE OF REGISTRATION OF CHARGE-20201030
Form DPT-3-18062020-signed
Form CHG-1-30032020-signed
CERTIFICATE OF REGISTRATION OF CHARGE-20200330
Optional Attachment-(1)-05032020
Optional Attachment-(3)-05032020
Optional Attachment-(5)-05032020
Optional Attachment-(2)-05032020
Optional Attachment-(4)-05032020
Instrument(s) of creation or modification of charge;-05032020
Form CHG-1-05032020_signed
CERTIFICATE OF REGISTRATION OF CHARGE-20200305
Copy of MGT-8-12122019
List of share holders, debenture holders;-12122019
Form MGT-7-12122019_signed
XBRL document in respect Consolidated financial statement-29112019
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-29112019
Form AOC-4(XBRL)-29112019_signed
Instrument(s) of creation or modification of charge;-15112019
Optional Attachment-(1)-15112019
Instrument(s) of creation or modification of charge;-12112019
Optional Attachment-(1)-12112019
Instrument(s) of creation or modification of charge;-07112019
Optional Attachment-(1)-07112019
Form CHG-1-31072019_signed
Instrument(s) of creation or modification of charge;-31072019
Optional Attachment-(2)-31072019
